Form 4: Edwards Lifesciences CEO Reports Stock Transactions

Sentiment:

Insider Transaction Report 13 February 2026 5:37 PM

📋All filings for Edwards Lifesciences CORP

Edwards Lifesciences CEO Bernard J. Zovighian reported the exercise of stock options and subsequent sale of common stock, alongside a gift of shares, on February 12-13, 2026.

Summary

Bernard J. Zovighian, CEO and Director of Edwards Lifesciences Corp, exercised 25,350 employee stock options at a price of $59.2567 per share on February 12, 2026.
On February 12, 2026, 2,532 common shares were sold at a weighted average price of $77.1287, with trades ranging from $77.080 to $77.225.
An additional 19,898 common shares were sold on February 12, 2026, at a weighted average price of $76.6133, with trades ranging from $76.080 to $77.075.
On February 13, 2026, 2,920 common shares were disposed of as a gift at a price of $0.0000.
Concurrently, 2,920 common shares were acquired by a Trust as a gift at a price of $0.0000 on February 13, 2026.
Following these transactions, direct beneficial ownership stands at 80,976 common shares.
Indirect beneficial ownership includes 11,516.5511 common shares held by a Trust and 3,655.5854 common shares in the Issuer's 401(k) Plan.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine insider transaction for compensation and personal financial management, with no significant positive or negative implications for the company's operational performance or future prospects.

Positives

The CEO exercised 25,350 employee stock options at a price of $59.2567, indicating a profit margin on subsequent sales given the higher sale prices.

Negatives

The CEO sold a total of 22,430 common shares (2,532 + 19,898) at weighted average prices of $77.1287 and $76.6133.
2,920 shares were gifted, reducing the CEO's direct beneficial ownership.

Future Outlook

Industry Context

StockSavvy.ai notes that insider transactions, such as option exercises and subsequent sales, are common for executives as part of their compensation and personal financial planning, and do not necessarily indicate a change in company fundamentals or outlook.

Key Dates

Date	Description
05/08/2019	Employee stock options were granted under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program.
02/12/2026	Date of option exercise and initial common stock sales.
02/13/2026	Date of common stock gift transactions.
05/07/2026	Expiration date of the exercised employee stock options.

Recommendation

hold

The Form 4 filing details routine insider transactions by the CEO, including the exercise of stock options and subsequent sales, which are common for executive compensation and personal financial planning. These transactions do not provide new fundamental information about Edwards Lifesciences' operational performance or future outlook, thus a 'hold' recommendation is appropriate as the filing itself does not warrant a change in investment thesis.

Keywords

Edwards Lifesciences, EW, Form 4, Insider Trading, Stock Options, CEO, Bernard J. Zovighian, Share Sale, Equity Transaction

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.